"Here, we investigate a β-cyclodextrin nanoparticle (CDNP) formulation encapsulating the Toll-like receptor 7 and 8 (TLR7/8) agonist R848 (CDNP-R848) to reprogram myeloid cells in the glioma microenvironment."

#immunology #TollLikeReceptor #InnateImmunity #Immunotherapy

https://www.nature.com/articles/s41467-023-36321-6